Patent intelligence · US
US 11400164
Immunoconjugates targeting HER2
Immunoconjugates targeting HER2
Patent details — US 11400164
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 2, 2022
- Expiration
- Jul 28, 2042
- Applicant
- Bolt Biotherapeutics, Inc.
- Claims
- 44
- CPC classes
- A61K, A61K39/395, A61K47/6801, A61K47/6803
Quick answer
US 11400164 (Immunoconjugates targeting HER2) is held by Bolt Biotherapeutics, Inc.. Status: granted. Granted Aug 2, 2022. Expires Jul 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Bolt Biotherapeutics, Inc.
- Grant date
- Expiration
- Claims
- 44
- CPC classes
- A61K, A61K39/395, A61K47/6801, A61K47/6803, A61K47/6835, A61K47/6849
More from Bolt Biotherapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12325750
Anti-Dectin-2 antibodies and methods of using
granted -
US 11753474
Anti-Dectin-2 antibodies
granted -
US 11654199
Thienoazepine immunoconjugates, and uses thereof
granted -
US 11547761
Antibody adjuvant conjugates
granted -
US 11110178
Antibody adjuvant conjugates
granted -
US 10675358
Antibody adjuvant conjugates
granted
Related coverage
Medicare price rule could hit Keytruda and Opdivo subcutaneous launches
CMS is proposing a Medicare drug price rule that could shape the outlook for subcutaneous Keytruda and Opdivo. The products are expected to be eligible for selection in the 2027 negotiation round for IPAY 2029.
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
FDA Approval VX-009: Market Analysis of Oncodex's Oncolytic Virus Therapy
Explore the implications of FDA-approved VX-009, Oncodex's groundbreaking oncolytic virus therapy, and its potential impact on the cancer treatment market.
Checkpoint Inhibitor Combinations Melanoma: Phase 3 Data & FDA Insights
This article delves into Phase 3 clinical trial data and FDA insights regarding checkpoint inhibitor combinations, focusing on their efficacy in treating melanoma.
Frequently asked questions
What is US patent 11400164?
US 11400164 (Immunoconjugates targeting HER2) is held by Bolt Biotherapeutics, Inc.. Status: granted. Granted Aug 2, 2022. Expires Jul 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11400164?
Bolt Biotherapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11400164 expire?
Our index shows an expiration date of Jul 28, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.